Arthneeti
Latest: Biocon Q1 FY27 (Apr–Jun 2026) results →This page is Q4 FY26 (Jan–Mar 2026).All Q4 FY26 results →
B

Biocon

Q4 FY26Pharmaceuticals & Biotechnology

Biocon Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹416
Market cap₹67.7K Cr
P/E93.1
Updated23 Aug 2026
Read4 min read

The short version

Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28. - Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27. - U.S. Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage.

From Biocon's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28.
  • Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27.
  • U.S. biosimilar business to gain momentum with launches like aflibercept (Yesafili) expected in H2 FY '27.
  • Generics business to scale up with improvements in profitability driven by higher volume and operating leverage; pipeline includes several upcoming launches.
  • Operating leverage to improve as capacity utilization rises in both biosimilars and generics.
  • Overall volume growth is steady, with a strong focus on sustainable and profitable expansion across all geographies.

2 more points from Biocon's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete. (Page 5)
  • The Malaysia facility capacity is being doubled for both drug substance and drug product, with drug product line qualification happening currently and drug substance doubling by end of FY '26. (Pages 15-16)
  • Minor debottlenecking at Bangalore may occur but no large greenfield capex is planned for FY '27 or FY '28. (Page 15)
  • Future capital allocation focus will be on profitable and sustainable growth, not large new expansions. (Page 19)

2 more points from Biocon's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion mainly focuses on biosimilar sales breakdown, product performance, capacity utilization, financial results, capital expenditure, and strategic priorities. For precise information on the current or expected orderbook or pending orders, please refer to other sections of the full earnings report or investor presentation not included here.

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Guj. Themis Bio. (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Q4 FY26 results?

Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28. - Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27. - U.S. Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage.

What is Biocon share price analysis?

Biocon currently shows a neutral. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete.

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.